Cargando…

In vivo effects of AZD4547, a novel fibroblast growth factor receptor inhibitor, in a mouse model of endometriosis

Endometriosis is a chronic disease, characterized by the growth of endometrial‐like cells outside the uterine cavity. Due to its complex pathophysiology, a totally resolving cure is yet to be found. The aim of this study was to compare the therapeutic efficacy of AZD4547, a novel fibroblast growth f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santorelli, Sara, Fischer, Deborah P., Harte, Michael K., Laru, Johanna, Marshall, Kay M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019068/ https://www.ncbi.nlm.nih.gov/pubmed/33811484 http://dx.doi.org/10.1002/prp2.759

Ejemplares similares

Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR-FGFR1 fusion
por: Qiu, Xu-Hua, et al.
Publicado: (2017)

In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3
por: Hwang, Gyoyeon, et al.
Publicado: (2017)

The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells
por: Na, Yu Ran, et al.
Publicado: (2021)

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
por: Saka, Hideo, et al.
Publicado: (2017)

Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2–Amplified Gastric Cancer Patient–Derived Cell Model()
por: Jang, Jiryeon, et al.
Publicado: (2017)

Targeted Inhibition of Fibroblast Growth Factor Receptor 1-GLI Through AZD4547 and GANT61 Modulates Breast Cancer Progression
por: Riaz, Syeda Kiran, et al.
Publicado: (2021)

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
por: Coombes, R. C., et al.
Publicado: (2022)

Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
por: Chang, Jinjia, et al.
Publicado: (2014)

Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer
por: Shan, Liping, et al.
Publicado: (2019)

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
por: Coombes, R. C., et al.
Publicado: (2023)

A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment
por: Kang, Jinho, et al.
Publicado: (2019)

FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
por: Zhao, Qingxia, et al.
Publicado: (2017)

Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study
por: Liang, Donglou, et al.
Publicado: (2017)

Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs
por: Cho, Hanna, et al.
Publicado: (2021)

Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
por: Kähkönen, T. E., et al.
Publicado: (2020)

AZD4547 Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting Inflammation: The Role of FGFR1 in Renal Tubular Epithelial Cells
por: Chen, Xuemei, et al.
Publicado: (2020)

The Inhibition of the FGFR/PI3K/Akt Axis by AZD4547 Disrupts the Proangiogenic Microenvironment and Vasculogenic Mimicry Arising from the Interplay between Endothelial and Triple-Negative Breast Cancer Cells
por: Morales-Guadarrama, Gabriela, et al.
Publicado: (2023)

ERCC1 rs11615 polymorphism increases susceptibility to breast cancer: a meta-analysis of 4547 individuals
por: Li, Bingjie, et al.
Publicado: (2018)

In Vitro and In Vivo Interactions of TOR Inhibitor AZD8055 and Azoles against Pathogenic Fungi
por: Sun, Yi, et al.
Publicado: (2022)

Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts
por: Scheper, Julian, et al.
Publicado: (2022)

Antidiarrheal Action of Bacillus subtilis CU1 CNCM I-2745 and Lactobacillus plantarum CNCM I-4547 in Mice
por: Urdaci, Maria C., et al.
Publicado: (2018)

4547 Understanding the molecular mechanism of natural killer cell deficiency to improve natural killer cell in vitro differentiation for therapeutics
por: Schmit, Megan, et al.
Publicado: (2020)

Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2015)

AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo
por: Cha, Byung-Hyun, et al.
Publicado: (2021)

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
por: Harada, Masako, et al.
Publicado: (2015)

Laparoscopically guided transversus abdominis plane block versus local wound analgesia in laparoscopic surgery for peritoneal endometriosis: study protocol for a prospective randomized controlled double-blinded LTAP-trial
por: Terho, Anna, et al.
Publicado: (2022)

Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo
por: Yan, Shuang, et al.
Publicado: (2013)

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo
por: Yasukawa, Masaaki, et al.
Publicado: (2016)

Corrigendum: Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2016)

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease
por: Simard, Jean-Christophe, et al.
Publicado: (2020)

In Vivo Anticancer Activity of AZD3965: A Systematic Review
por: Silva, Ana, et al.
Publicado: (2021)

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
por: Wang, Yongfeng, et al.
Publicado: (2016)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo
por: Bi, Shuning, et al.
Publicado: (2019)

In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment
por: Benyahia, Zohra, et al.
Publicado: (2021)

Intraperitoneal inflammation decreases endometriosis in a mouse model
por: Nowak, N.M., et al.
Publicado: (2008)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2011)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2014)

In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor
por: Schöffski, Patrick, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bo40mkhl4e2m8a5epvuj4rjl19